Has Boadie Dunlop, MD received payments from drug or device companies?

Yes. Drug and device makers reported $60,573 in general payments to Boadie Dunlop, MD across 49 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Boadie Dunlop, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Boadie Dunlop, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Boadie Dunlop, MD

Psychiatry · Atlanta, GANPI 1558467605

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $58,158 of the $60,573 with a category attached, or 96.0%. Otsuka Pharmaceutical Development & Commercialization, Inc. accounts for 81.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $29,049 and has fallen 98.1% since, to $537 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,573in general payments, 2019–2025

Across 49 payments — averaging $1236.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Otsuka Pharmaceutical Development & Commercialization, Inc.$49K
Greenwich Biosciences, Inc.$6K
Sage Therapeutics, LLC$5K
Livanova USA, Inc.$132

$286,523in research payments, 2019–2025

Across 55 payments — averaging $5209.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Acadia Pharmaceuticals Inc$133K
Boehringer Ingelheim$92K
Sage Therapeutics, LLC$31K
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22K
Boehringer Ingelheim Pharma GmbH & Co.kg$8K

What the payments were for

Consulting fees$58,15896%
Travel & lodging$1,6733%
Food & beverage$7421%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Otsuka Pharmaceutical Development & Commercialization, Inc.	38	$49,356
Greenwich Biosciences, Inc.	1	$5,775
Sage Therapeutics, LLC	9	$5,310
Livanova USA, Inc.	1	$132

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

REXULTI$5,868
Epidiolex$5,775
ABILIFY MYCITE$980
VNS Therapy Symmetry Model 8103 Generator$132

How this compares

$60,573 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Medicare billing

Part B allowed, 2024

$8,467

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BelsomraSuvorexant	19	$8,371
Duloxetine Hcl	26	$1,331
Trazodone Hcl	30	$746
Clonazepam	58	$736
Olanzapine	33	$694
Bupropion XlBupropion Hcl	24	$679
Lamotrigine	27	$637
Buspirone Hcl	37	$596
Gabapentin	42	$570
Lithium Carbonate ErLithium Carbonate	17	$488
Mirtazapine	25	$440
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	13	$257
Aripiprazole	19	$200
Alprazolam	41	$157
Venlafaxine Hcl ErVenlafaxine Hcl	15	$146

Paid to pharmacies, not to this prescriber.

Other psychiatry in Atlanta

David PurselleAtlanta$307K
Michael BurkeAtlanta$217K
Bryon EvansAtlanta$211K
Kerry ResslerAtlanta$196K
Patricio Riva PosseAtlanta$122K
Ray HorwitzAtlanta$64K
Zohaib HaqueAtlanta$49K
Raymond KotwickiAtlanta$44K
Joseph BergerAtlanta$24K
Dwight OwensAtlanta$24K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →